Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Within Cardiovascular, Medtronic is gaining market share, banking on product launches in Cardiac Rhythm Management (CRM) and Structural Heart. CRM, one of Medtronic’s largest businesses ...

Medtronic (NYSE: MDT) today reported study results highlighting AFib detection with its Linq family of insertable cardiac monitors (ICM).

Medtronic Plc is a medical ... The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease.

On Monday, CEO Geoff Martha told investors the company’s product pipeline is now well-positioned to drive improved earnings. Medtronic's biggest businesses, which include cardiac rhythm management, ...

MDT stock is currently trading above its 50-day and 200-day moving averages. The stock witnessed a golden crossover on Sept.

Norm has received breakthrough device designation from the Food and Drug Administration, giving Fire1 additional access to ...

becoming the third device company to offer a PFA system in the U.S. Physicians have quickly adopted Boston Scientific’s and ...